Press |

Apalutamide en ADT bij nmCRPC

Adding apalutamide to androgen-deprivation therapy (ADT) leads to a fast, sustained drop in prostate-specific antigen (PSA) levels in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), and this reduction is linked with better outcomes, according to a post hoc analysis of data from the SPARTAN trial.

In ‘European Urology’ Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN

Meer op DUOS

Lees meer over de effectiviteit van apalutamide bij ‘Nieuwe gegevens behandeling uitgezaaide prostaatkanker’

 

© 2022, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in